1.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 001-0015-211, NCT00127387
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMR PH GL 2007 CL 001, NCT00547651
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-30504, CALGB 30504, NCT00453154
|
|
4.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-822, NCT00445198
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
7.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-446, NCT00508443
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-4047-SCLC-002, NCT00537511
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GEM017, NCT00682981
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 08-005, NCT00702962
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UMN-2008LS035, UMN-2008LS035, UMN-0803M29541, NCT00769990
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060534, NCT00791154
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: F080929010, UAB 0818, NCT00856830
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GLO-03-06-06, NCT00083161
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: HSC-MS-04-259, NCT00178698
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 565.04, BCC-LUN-04-002, NCT00265200
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: CTCT 05-01, NCT00379665
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
19.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UNC-LCCC-0519, LCCC 0519, NCT00454324
|
|
21.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MCC-15206, MCC-IRB-9792, MCC 15206, INTROGEN-RAC-0705-857, NCT00618891
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUN06-113, NCT00613626
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI LUN 156, NCT00695292
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-8507, CASE8507, CASE-8507-CC486, NCT00726986
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-065, NCT00740636
|
